Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.

Bryan MC, Drobnick J, Gobbi A, Kolesnikov A, Chen Y, Rajapaksa N, Ndubaku C, Feng J, Chang W, Francis R, Yu C, Choo EF, DeMent K, Ran Y, An L, Emson C, Huang Z, Sujatha-Bhaskar S, Brightbill H, DiPasquale A, Maher J, Wai J, McKenzie BS, Lupardus PJ, Zarrin AA, Kiefer JR.

J Med Chem. 2019 Jul 11;62(13):6223-6240. doi: 10.1021/acs.jmedchem.9b00439. Epub 2019 May 24.

PMID:
31082230
2.

Development of a mass spectrometry-based tryptophan 2, 3-dioxygenase assay using liver cytosol from multiple species.

Wang J, Takahashi RH, DeMent K, Gustafson A, Kenny JR, Wong SG, Yan Z.

Anal Biochem. 2018 Sep 1;556:85-90. doi: 10.1016/j.ab.2018.06.025. Epub 2018 Jun 28.

PMID:
29959909
3.

Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).

Pei Z, Mendonca R, Gazzard L, Pastor R, Goon L, Gustafson A, VanderPorten E, Hatzivassiliou G, Dement K, Cass R, Yuen PW, Zhang Y, Wu G, Lin X, Liu Y, Sellers BD.

ACS Med Chem Lett. 2018 Apr 2;9(5):417-421. doi: 10.1021/acsmedchemlett.7b00427. eCollection 2018 May 10.

4.

Practical strategies when using a stable isotope labeled microtracer for absolute bioavailability assessment: A case study of a high oral dose clinical candidate GDC-0810.

Chen B, Lu P, Freeman D, Gao Y, Choo E, DeMent K, Savage S, Zhang K, Milanwoski D, Liu L, Dean B, Deng Y.

J Pharm Biomed Anal. 2018 May 30;154:116-122. doi: 10.1016/j.jpba.2018.02.050. Epub 2018 Feb 23.

PMID:
29549853
5.

Preparation and evaluation of L- and D-5-[18F]fluorotryptophan as PET imaging probes for indoleamine and tryptophan 2,3-dioxygenases.

Tang T, Gill HS, Ogasawara A, Tinianow JN, Vanderbilt AN, Williams SP, Hatzivassiliou G, White S, Sandoval W, DeMent K, Wong M, Marik J.

Nucl Med Biol. 2017 Aug;51:10-17. doi: 10.1016/j.nucmedbio.2017.05.001. Epub 2017 May 5.

PMID:
28511073
6.

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in mice.

Lee DU, Katavolos P, Palanisamy G, Katewa A, Sioson C, Corpuz J, Pang J, DeMent K, Choo E, Ghilardi N, Diaz D, Danilenko DM.

Toxicol Appl Pharmacol. 2016 Jun 1;300:47-54. doi: 10.1016/j.taap.2016.03.013. Epub 2016 Apr 11.

PMID:
27078884
7.

Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.

Choo EF, Woolsey S, DeMent K, Ly J, Messick K, Qin A, Takahashi R.

Drug Metab Dispos. 2015 Jun;43(6):864-9. doi: 10.1124/dmd.115.063743. Epub 2015 Mar 26.

PMID:
25813936
8.

Biotransformation and bioactivation reactions of alicyclic amines in drug molecules.

Bolleddula J, DeMent K, Driscoll JP, Worboys P, Brassil PJ, Bourdet DL.

Drug Metab Rev. 2014 Aug;46(3):379-419. doi: 10.3109/03602532.2014.924962. Epub 2014 Jun 9. Review.

PMID:
24909234

Supplemental Content

Loading ...
Support Center